Dr.Reddy's Laboratories Ltd

BSE: 500124 NSE: DRREDDY
Dr.Reddy's Laboratories Ltd - pharma in Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN L85195TG1984PLC004507 Incorporated 24 February 1984 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: DRREDDY · BSE: 500124 Public Limited Company pharma
Data last updated
Revenue · FY 2025
₹33,741 Cr
▲ 17.00% YoY
EBITDA · FY 2025
*****
▲ 9.00% YoY
Net profit · FY 2025
*****
▲ 3.00% YoY
Authorised capital
₹145 Cr
Registered with MCA
Paid-up capital
₹83.46 Cr
Issued & subscribed
Open charges
₹34.23 Cr
Satisfied ₹586.71 Cr
Company age
42 yrs
Est. 1984
Employees · EPFO
7,985
Latest available

About Dr.Reddy's Laboratories Ltd

Data last updated: 06 February 2026

Dr.Reddy's Laboratories Ltd is a public limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 24 February 1984, the company has been in operation for over 42 years.

Registered with ROC Hyderabad under CIN L85195TG1984PLC004507. Listed on BSE: 500124 and NSE: DRREDDY.

Capital: an authorised share capital of ₹145 Cr and a paid-up capital of ₹83.46 Cr. Formerly known as Dr.Reddy'S Laboratories P Ltd. It is led by directors including Kodumudi Pranatharthiharan Krishnan and Leo Puri.

Last AGM: 24 July 2025. Financial statements filed for year ended 31 March 2025. Office: 8 – 2 – 337 Road No. 3 Banjara Hills, Hyderabad, Telangana, India – 500034.

As per the financials filed for FY 2025, the company reported a revenue of ₹33,741 Cr, a growth of 17% compared to the previous year.

The company has a workforce of approximately 7,985 employees as per the latest available data. Its group structure includes 9 subsidiaries and 1 joint venture.

The company is associated with 3 brands - Aurigene, Studio 5B, Dr. Reddy's Laboratories. As per MCA filings, the company has open charges of ₹34.23 Cr and satisfied charges of ₹586.71 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website drreddys.com.

Company Details of Dr.Reddy's Laboratories Ltd
CIN L85195TG1984PLC004507
Registration Number 004507
Incorporation Date 24 February 1984
ROC Hyderabad
Listing Status Listed (BSE: 500124, NSE: DRREDDY)
Company Status Active
Date of Last AGM 24 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Venkateswara Prasad Gunupati Managing Director Satish Reddy Kallam Whole-Time Director Kodumudi Pranatharthiharan Krishnan Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    drreddys.com
  • Social Media
  • Registered Address
    8 – 2 – 337 Road No. 3 Banjara Hills, Hyderabad, Telangana, India – 500034
  • Industry
    Pharma, Drug Formulation & Development
Company report
Dr.Reddy's Laboratories Ltd - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Dr.Reddy's Laboratories Ltd report

Financials, compliance, directors, charges, ownership and filings for Dr.Reddy's Laboratories Ltd in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd has one previous CIN (Corporate Identification Number): L85195AP1984PLC004507. The current CIN is L85195TG1984PLC004507, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L85195TG1984PLC004507 Current
L85195AP1984PLC004507 Previous

Associated Brands with Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd operates multiple associated brands including Aurigene, Studio 5b, and Dr. Reddy's Laboratories. These brands represent Dr.Reddy's Laboratories Ltd's diversified market presence and brand portfolio.

Brand Description Website
Aurigene
Discovers and develops novel oncology therapeutics via research collaborations. aurigene.com
Dr. Reddy's Laboratories
Innovative medicines are developed and manufactured globally by the company. drreddys.com
Studio 5b
Design of people-centric healthcare solutions globally. studio-5b.com

Competitors & Alternatives of Dr.Reddy's Laboratories Ltd

Brands and companies operating in the same space as Dr.Reddy's Laboratories Ltd include Sutro Biopharma, Synthego, Avidity Biosciences and 7 more.

Competitor Description Location Founded
Sutro Biopharma Sutro Biopharma Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. United States 2003
Synthego Synthego CRISPR-engineered cell and gene therapies are developed for research applications. Redwood City, United States, United States 2012
Avidity Biosciences Avidity Biosciences Antibody-siRNA complexes are developed for cancer treatment. San Diego, United States, United States 2012
Antheia Antheia Yeast cells are genetically engineered to produce medicinal products. Palo Alto, United States, United States 2013
Vividion Therapeutics Vividion Therapeutics Developing novel drugs based on a proteome-wide ligand and target discovery platform Oceanside, United States, United States 2016
Korro Bio Korro Bio RNA-editing technologies are provided for precision medicine applications. Cambridge, United States, United States 2018
Straumann Group Straumann Group Dental implants and regenerative dentistry products are developed. Basel, Switzerland, Switzerland 1954
Judges Scientific Judges Scientific Acquisition and development of scientific instrument businesses is conducted. London, United Kingdom, United Kingdom 2002
Savara Pharma Savara Pharma Therapeutics for rare respiratory diseases are developed by Savara Pharma. Austin, United States, United States 2008
Univercells Univercells Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. Charleroi, Belgium, Belgium 2013

Business Activity of Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd is audited by S.R. Batliboi & Associates LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
S.R. Batliboi & Associates LLP blur-value blur-value blur-value

Board of Directors of Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd is currently managed by 13 directors, with 33 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Kodumudi Pranatharthiharan Krishnan
Also directs: Tata Consumer Products Limited, Asrec (India) Limited, Helios Trustee Private Limited and 3 more
Director 07 Jan 2022 4 Years 6 Months Current
Leo Puri
Also directs: Fortis Healthcare Limited
Director 25 Oct 2018 7 Years 8 Months Current
Arun Madhavan Kumar
Also directs: Celesta India Aif Llp, Celesta India Aif Managers Llp, Agnikul Cosmos Private Limited
Director 01 Aug 2022 3 Years 11 Months Current
Satish Reddy Kallam
Also directs: Aurigene Oncology Limited, Greenpark Hotels And Resorts Limited, Stamlo Industries Limited and 5 more
Whole-Time Director 18 Jan 1993 33 Years 5 Months Current
Venkateswara Prasad Gunupati
Also directs: Aurigene Oncology Limited, Greenpark Hotels And Resorts Limited, Idea2enterprises (India) Private Limited and 4 more
Managing Director 08 Apr 1986 40 Years 3 Months Current
Alpna Hansraj Seth Director 19 Sep 2023 2 Years 9 Months Current
Showing 6 of 13 current directors. View all directors

Financials of Dr.Reddy's Laboratories Ltd FY 2025 filings available

Dr.Reddy's Laboratories Ltd reported revenue of ₹33,741 Cr (up 17% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue
₹33,741 Cr ▲ 17%
Profit
***** ▲ 3%
EBITDA
***** ▲ 9%
Metrics
*****
*****
*****
*****
*****
Revenue
Revenue from Operations
*****
*****
*****
*****
*****
Revenue Growth %
*****
*****
*****
*****
*****
Other Income
*****
*****
*****
*****
*****
Total Revenue
*****
*****
*****
*****
*****
Expenses
Total Expenses
*****
*****
*****
*****
*****
Raw Material Cost
*****
*****
*****
*****
*****
Change in Inventory FG
*****
*****
*****
*****
*****
Change in Inventory WIP
*****
*****
*****
*****
*****
Purchase of Traded Goods
*****
*****
*****
*****
*****
Employee Cost
*****
*****
*****
*****
*****
Managerial Remuneration
*****
*****
*****
*****
*****
Audit Fees
*****
*****
*****
*****
*****
Insurance
*****
*****
*****
*****
*****
Power & Fuel
*****
*****
*****
*****
*****
Interest
*****
*****
*****
*****
*****
Depreciation
*****
*****
*****
*****
*****
Other Expenses
*****
*****
*****
*****
*****
Profitability
EBITDA (Operating Profit)
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
Exceptional Items
*****
*****
*****
*****
*****
Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Exceptional & Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Tax
*****
*****
*****
*****
*****
Tax & Net Profit
Tax Expense
*****
*****
*****
*****
*****
Current Tax
*****
*****
*****
*****
*****
Deferred Tax
*****
*****
*****
*****
*****
Profit from Discontinued Operations
*****
*****
*****
*****
*****
Tax on Discontinued Operations
*****
*****
*****
*****
*****
Profit
*****
*****
*****
*****
*****
Net Margin %
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Shareholders' Funds
Total Shareholders' Funds
*****
*****
*****
*****
*****
Equity Capital
*****
*****
*****
*****
*****
Reserves & Surplus
*****
*****
*****
*****
*****
Money Against Warrants
*****
*****
*****
*****
*****
Other Equity
*****
*****
*****
*****
*****
Non-Current Liabilities
Total Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Borrowings
*****
*****
*****
*****
*****
Deferred Tax Liabilities
*****
*****
*****
*****
*****
Other Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Provisions
*****
*****
*****
*****
*****
Current Liabilities
Total Current Liabilities
*****
*****
*****
*****
*****
Short-Term Borrowings
*****
*****
*****
*****
*****
Trade Payables
*****
*****
*****
*****
*****
Other Current Liabilities
*****
*****
*****
*****
*****
Short-Term Provisions
*****
*****
*****
*****
*****
Total Equity & Liabilities
*****
*****
*****
*****
*****
Non-Current Assets
Non-Current Assets
*****
*****
*****
*****
*****
Tangible Assets
*****
*****
*****
*****
*****
Intangible Assets
*****
*****
*****
*****
*****
Capital WIP
*****
*****
*****
*****
*****
Intangibles Under Dev
*****
*****
*****
*****
*****
Investments
*****
*****
*****
*****
*****
Deferred Tax Assets
*****
*****
*****
*****
*****
LT Loans & Advances
*****
*****
*****
*****
*****
Other Non-Current Assets
*****
*****
*****
*****
*****
Current Assets
Current Assets
*****
*****
*****
*****
*****
Current Investments
*****
*****
*****
*****
*****
Inventories
*****
*****
*****
*****
*****
Trade Receivables
*****
*****
*****
*****
*****
Cash & Bank Balance
*****
*****
*****
*****
*****
ST Loans & Advances
*****
*****
*****
*****
*****
Other Current Assets
*****
*****
*****
*****
*****
Total Assets
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Cash from Operating Activities (CFO)
Profit Before Tax
*****
*****
*****
*****
*****
Non-Cash Adjustments
*****
*****
*****
*****
*****
+ Interest Expense
*****
*****
*****
*****
*****
+ Depreciation
*****
*****
*****
*****
*****
+/- Unrealized Forex
*****
*****
*****
*****
*****
- Dividend Income
*****
*****
*****
*****
*****
- Interest Income
*****
*****
*****
*****
*****
+/- Other Non-Cash Items
*****
*****
*****
*****
*****
Changes in Working Capital
*****
*****
*****
*****
*****
+/- Inventory
*****
*****
*****
*****
*****
+/- Debtors
*****
*****
*****
*****
*****
+/- Creditors
*****
*****
*****
*****
*****
Reconciliation Adjustments
*****
*****
*****
*****
*****
Cash Generated from Operations
*****
*****
*****
*****
*****
Income Taxes Paid
*****
*****
*****
*****
*****
Net CFO (Cash from Operations)
*****
*****
*****
*****
*****
Cash from Investing Activities (CFI)
Acquisitions & Disposals
*****
*****
*****
*****
*****
Disposal of Subsidiaries
*****
*****
*****
*****
*****
Acquisition of Subsidiaries
*****
*****
*****
*****
*****
Capex
*****
*****
*****
*****
*****
Purchase of Fixed Assets
*****
*****
*****
*****
*****
Sale of Fixed Assets
*****
*****
*****
*****
*****
Other Investing Cash Flows
*****
*****
*****
*****
*****
Net CFI (Cash from Investing)
*****
*****
*****
*****
*****
Cash from Financing Activities (CFF)
Equity Issuance
*****
*****
*****
*****
*****
Debt Raised
*****
*****
*****
*****
*****
Debt Repaid
*****
*****
*****
*****
*****
Dividends Paid
*****
*****
*****
*****
*****
Interest Paid
*****
*****
*****
*****
*****
Net CFF (Cash from Financing)
*****
*****
*****
*****
*****
Net Cash Position
Net Change in Cash (Pre-Forex)
*****
*****
*****
*****
*****
Closing Cash & Equivalents
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Liquidity
Current Ratio
*****
*****
*****
*****
*****
Quick Ratio
*****
*****
*****
*****
*****
Cash Ratio
*****
*****
*****
*****
*****
Efficiency
Inventory Days
*****
*****
*****
*****
*****
Debtor Days
*****
*****
*****
*****
*****
Creditor Days
*****
*****
*****
*****
*****
Cash Conversion Cycle
*****
*****
*****
*****
*****
Asset Turnover
*****
*****
*****
*****
*****
Profitability
Net Profit Margin %
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
ROE %
*****
*****
*****
*****
*****
ROCE %
*****
*****
*****
*****
*****
Net Worth Margin %
*****
*****
*****
*****
*****
Growth
Revenue Growth %
*****
*****
*****
*****
*****
Leverage
Equity Multiplier
*****
*****
*****
*****
*****
Debt / EBITDA
*****
*****
*****
*****
*****
Solvency
D/E Ratio
*****
*****
*****
*****
*****
ICR
*****
*****
*****
*****
*****

Consolidated Statements

Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.

Unlock Complete Financial History (FY 2015 – Latest)
Standalone & Consolidated - Income Statement, Balance Sheet, Cash Flow, Financial Ratios and Growth Trends with 10+ years of line-item data.
10+ years of data Line-item breakdown Balance Sheet detail Cash Flow analysis 20+ ratios & metrics Downloadable PDF

Shareholding Pattern of Dr.Reddy's Laboratories Ltd

As of FY 2022, Dr.Reddy's Laboratories Ltd's shareholding pattern shows 26.71% by promoters, 24.47% by domestic institutional investors (DII), 25.16% by foreign institutional investors (FII), 11.64% by public shareholders, 12.02% by others.

2025
YEAR
38.19% Promoters
25.22% DII (Domestic Institutional)
10.28% FII (Foreign Institutional)
25.89% Public
2.42% Others
Shareholding Trend
Year 2025
Promoters 33.19%
DII 23.22%
FII 18.28%
Public 22.89%
Others 2.42%

Group Structure of Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd has 9 subsidiary companies and 1 joint venture. This group structure data is as of FY 2022. The corporate group structure reflects Dr.Reddy's Laboratories Ltd's business expansion strategy and organizational complexity.

9
Subsidiary companies
1
Joint ventures
Key Subsidiaries
Company Name CIN Shares Held
Imperial Credit Private Limited U06519TG1991PTC126383
**.**%
Aurigene Discovery Technologies Limited U24239KA2001PLC029391
**.**%
Dr. Reddys Formulations Limited U24299TG2021PLC149527
**.**%
Drl Impex Limited U65990TG1986PLC006695
**.**%
Cheminor Investments Limited U67120TG1990PLC010931
**.**%
Dr. Reddys Bio-Sciences Limited U72200TG2000PLC034765
**.**%

Showing major subsidiaries. Total: 9.

Charges & Borrowings of Dr.Reddy's Laboratories Ltd

Open charges
₹34.23 Cr
Satisfied charges
₹586.71 Cr
Breakdown by lending institutions
Globaltrust Bank Ltd₹20.00 Cr
Global Trust Bank Ltd₹7.60 Cr
Global Tust Bank Ltd₹5.50 Cr
Industrial Finance Corp. of India₹0.45 Cr
Andhra Bank₹0.25 Cr
Others₹0.43 Cr
Latest charge details
DateLenderAmountStatus
02 Aug 1996 Globaltrust Bank Ltd ₹10 Cr Open
19 Feb 1996 Globaltrust Bank Ltd ₹10 Cr Open
20 Dec 1995 Global Trust Bank Ltd ₹5 Cr Open
04 Dec 1995 Global Trust Bank Ltd ₹2.6 Cr Open
06 Jul 1995 Global Tust Bank Ltd ₹5.5 Cr Open

Total charge records: 95 View all charges

Employees and EPFO Compliance at Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd has a workforce of 7,985 employees as of Nov 14, 2024.

Employee count
7,985
Active EPFO establishments
3
Employee growth
7.14%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Dr.Reddy's Laboratories Ltd

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Dr.Reddy's Laboratories Ltd

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Dr.Reddy's Laboratories Ltd

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Dr.Reddy's Laboratories Ltd

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Dr.Reddy's Laboratories Ltd

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Dr.Reddy's Laboratories Ltd

MSME Payment Delays by Dr.Reddy's Laboratories Ltd

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Dr.Reddy's Laboratories Ltd

Subsidiaries & Group Companies of Dr.Reddy's Laboratories Ltd

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Dr.Reddy's Laboratories Ltd with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Dr.Reddy's Laboratories Ltd

MCA Filings & Documents of Dr.Reddy's Laboratories Ltd

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Dr.Reddy's Laboratories Ltd

Activity
24 Jul 2025
Dr.Reddy'S Laboratories Ltd last Annual general meeting of members was held on 24 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Dr.Reddy'S Laboratories Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
28 Aug 2024
Mannam Venkata Narasimham was appointed as a Cfo on 28 Aug 2024 & has been associated with this company since 1 year 10 months.
Directors
29 Dec 2023
Sanjiv Soshil Mehta was appointed as a Director on 29 Dec 2023 & has been associated with this company since 2 years 6 months.
Directors
19 Sep 2023
Alpna Hansraj Seth was appointed as a Director on 19 Sep 2023 & has been associated with this company since 2 years 9 months.
Directors
10 May 2023
Claudio Dr Albrecht was appointed as a Director on 10 May 2023 & has been associated with this company since 3 years 2 months.

Recent News on Dr.Reddy's Laboratories Ltd

Sensex snaps 7-day rally; HUL weighs on FMCG stocks
24 Apr 2025 · Thehindubusinessline
No workforce reduction: Dr. Reddy’s
14 Apr 2025 · Thehindubusinessline

Frequently Asked Questions about Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 24 February 1984 (42+ years old) and is registered under CIN L85195TG1984PLC004507. Listed on BSE: 500124 and NSE: DRREDDY. The company has 7,985 employees.

Dr.Reddy's Laboratories Ltd reported revenue of ₹33,741 Cr for FY 2025 (up 17.00% YoY).

The current directors of Dr.Reddy's Laboratories Ltd are:

The primary industry of Dr.Reddy's Laboratories Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Dr.Reddy's Laboratories Ltd is listed on both BSE (code: 500124) and NSE (symbol: DRREDDY).

Dr.Reddy's Laboratories Ltd can be reached at the registered office: 8 – 2 – 337 Road No. 3 Banjara Hills, Hyderabad, Telangana, India – 500034, or through the website drreddys.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available